Invitrocue Appendix 4C and Business updates

The Reporting Period represents another successful period of advancements for Invitrocue.

October 31, 2018 – InvitroCue Limited (ASX: IVQ), a leading healthcare bio-analytic solutions provider, has released its Appendix 4C for the quarter ended 30 September 2018 (Reporting Period). In addition to the financial results as disclosed in the announcement, Invitrocue provides the following highlights of the company from the Reporting Period.

Highlights of the Reporting Period include:

  • Incorporation of a Hong Kong corporate entity
  • Recruitment of the first patient sample from Malaysia as part of Invitrocue’s regional expansion
  • Receipt of grant from the Chinese government to conduct validation work on lung cancer models of Onco-PDOTM
  • Laboratory team expansion in China in advance of accelerating marketing efforts
  • Inaugural global oncology summit of key opinion leaders held in Germany

The Reporting Period represents another successful period of advancements for Invitrocue. We continue to focus on our strategy to roll-out Onco-PDOTM in international markets, establishing corporate entities in key markets and ensuring our laboratory facilities are staffed with skilled technicians in advance of offering our innovative screening technology in a growing number of locations. A regional roll-out program in South East Asia is underway and the first patient sample from Malaysia was received during the Reporting Period.

In-line with our strategy to establish new corporate entities in the markets in which we offer Onco- PDO, the company established its Hong Kong corporate entity during the Reporting Period. In preparation of launching Onco-PDO in China, we have been working closely with our partners at Suzhou University Hospital to validate lung cancer models. During the Reporting Period, Invitrocue was awarded RMB333,000 (approx. S$65,000) as a share of grant funding awarded to Suzhou University, its affiliated hospital and Invitrocue by the Chinese government to facilitate this work.

Education on our ground-breaking technology remains an important aspect of our strategy in this important early phase of marketing. On 1 October, we were proud to bring together international experts on oncology, precision medicine, and biochemistry from leading global institutes, cancer centres and universities for Invitrocue’s inaugural education summit for clinicians titled Oncology: The future of cancer treatment. During the summit, international speakers presented on cutting- edge innovations and recent findings in the field of oncology and clinicians shared their experiences of using Onco-PDO as an innovative solution and leading technology to empower patients and their physicians to improve potential treatment outcomes.

Invitrocue’s Annual General Meeting will be held on Thursday, 29 November at 11:00am at the offices of Deloitte Sydney, Level 9, Grosvenor Place, 225 George Street, NSW 2000.

Commenting on the quarterly performance, Dr Steven Fang, Executive Director, Invitrocue, said:

“It has been another quarter of growth for Invitrocue as we scale our operations and build up commercial capabilities in key markets, as our proprietary Onco-PDO sees rising awareness, interest and recognition amongst physicians and thought leaders in personalised oncology industry. Onco- PDO is the leading personalised oncology treatment screening for cancer patients and we look forward to bringing it to more physicians and patients worldwide.”

Conference call details

There will be a conference call for investors and analysts on 2 November 2018, hosted by Executive Director, Dr Steven Fang. If you wish to submit questions in advance please direct them to Invitrocue@spurwingcomms.com

Friday, 2 November 2018

16:00 Sydney, +61 (0) 2 8015 2088
14:00 Singapore, +65 3158 7288
07:00 Munich, +49 (0) 30 3080 6188
06:00 London, +44 (0) 20 3051 2874

Access Code: 984 133 999

To join the call from PC, Mac, Linux, iOS or Android click here. Additional international numbers available here.

- ENDS -


For more information contact:
Martin D. Bach, VP Operations
T: +65 6460 0490
martind.bach@invitrocue.com

About Invitrocue
Invitrocue is a leading healthcare bio-analytic solutions provider including in vitro cell-based testing technologies and image analytics software for use in digital pathology. Invitrocue has developed a unique 3D cell-based scaffolding technology that mimics human organ samples for using in the field of infectious diseases. In 2016, the company expanded its work in liver disease to the field of oncology. Invitrocue’s Onco-PDOTM technology enables patient-derived cancer cells (organoids) to be cultured in laboratories for testing against a panel of drugs to support clinical decision making for individual patients (personalised medicine).

Invitrocue’s technology originated in Singapore’s Agency for Science, Technology and Research (A*STAR). Invitrocue has been developed and validated in partnerships with leading biopharmaceutical companies and scientific collaborators.

Invitrocue is listed on the Australian Securities Exchange under the ticker IVQ. Website: www.invitrocue.com

MORE ON THIS TOPIC